Chilton Capital Management’s Novo Nordisk NVO Stock Holding History

Chilton Capital Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1M	Buy	20,947 +326	+2%	+$14K	0.03%	130
2026 Q1	$758K	Sell	20,621 -466	-2%	-$22.1K	0.03%	147
2025 Q4	$1.07M	Sell	21,087 -175	-0.8%	-$8.95K	0.04%	126
2025 Q3	$1.18M	Sell	21,262 -568	-3%	-$33.2K	0.04%	127
2025 Q2	$1.51M	Buy	21,830 +1,283	+6%	+$87.3K	0.06%	114
2025 Q1	$1.43M	Buy	20,547 +547	+3%	+$45.2K	0.06%	108
2024 Q4	$1.72M	Hold	20,000	–	–	0.07%	104
2024 Q3	$2.38M	Sell	20,000 -2,116	-10%	-$282K	0.1%	94
2024 Q2	$3.16M	Buy	22,116 +2,000	+10%	+$265K	0.14%	86
2024 Q1	$2.58M	Buy	20,116 +116	+0.6%	+$13.8K	0.12%	92
2023 Q4	$2.07M	Hold	20,000	–	–	0.11%	104
2023 Q3	$1.82M	Sell	20,000 -126	-0.6%	-$11.1K	0.1%	101
2023 Q2	$1.63M	Buy	20,126 +126	+0.6%	+$10.3K	0.09%	101
2023 Q1	$1.59M	Hold	20,000	–	–	0.09%	103
2022 Q4	$1.35M	Hold	20,000	–	–	0.08%	111
2022 Q3	$996K	Hold	20,000	–	–	0.07%	121
2022 Q2	$1.11M	Hold	20,000	–	–	0.07%	122
2022 Q1	$1.11M	Hold	20,000	–	–	0.06%	125
2021 Q4	$1.12M	Hold	20,000	–	–	0.06%	126
2021 Q3	$960K	Hold	20,000	–	–	0.05%	125
2021 Q2	$838K	Hold	20,000	–	–	0.05%	131
2021 Q1	$674K	Hold	20,000	–	–	0.04%	135
2020 Q4	$699K	Hold	20,000	–	–	0.05%	123
2020 Q3	$694K	Sell	20,000 -186	-0.9%	-$6.2K	0.05%	126
2020 Q2	$661K	Buy	20,186 +186	+0.9%	+$5.93K	0.06%	124
2020 Q1	$602K	Sell	20,000 -1,000	-5%	-$29.8K	0.06%	126
2019 Q4	$608K	Hold	21,000	–	–	0.05%	145
2019 Q3	$543K	Sell	21,000 -1,000	-5%	-$25.3K	0.04%	153
2019 Q2	$561K	Buy	22,000 +2,000	+10%	+$49.4K	0.05%	149
2019 Q1	$523K	Sell	20,000 -140	-0.7%	-$3.44K	0.05%	150
2018 Q4	$464K	Hold	20,140	–	–	0.05%	155
2018 Q3	$475K	Hold	20,140	–	–	0.04%	170
2018 Q2	$464K	Buy	20,140 +140	+0.7%	+$3.33K	0.04%	171
2018 Q1	$493K	Hold	20,000	–	–	0.04%	159
2017 Q4	$537K	Hold	20,000	–	–	0.05%	136
2017 Q3	$482K	Hold	20,000	–	–	0.05%	132
2017 Q2	$429K	Hold	20,000	–	–	0.05%	122
2017 Q1	$343K	Hold	20,000	–	–	0.03%	123
2016 Q4	$359K	Sell	20,000 -3,482	-15%	-$63.1K	0.04%	119
2016 Q3	$488K	Hold	23,482	–	–	0.05%	126
2016 Q2	$631K	Sell	23,482 -816	-3%	-$22.4K	0.06%	120
2016 Q1	$658K	Hold	24,298	–	–	0.07%	118
2015 Q4	$706K	Buy	24,298 +4,298	+21%	+$119K	0.07%	116
2015 Q3	$542K	Hold	20,000	–	–	0.06%	120
2015 Q2	$548K	Hold	20,000	–	–	0.05%	127
2015 Q1	$534K	Hold	20,000	–	–	0.05%	132
2014 Q4	$423K	Hold	20,000	–	–	0.04%	143
2014 Q3	$476K	Hold	20,000	–	–	0.05%	130
2014 Q2	$462K	Hold	20,000	–	–	0.05%	134
2014 Q1	$457K	Hold	20,000	–	–	0.05%	133
2013 Q4	$370K	Hold	20,000	–	–	0.04%	154
2013 Q3	$338K	Hold	20,000	–	–	0.04%	165
2013 Q2	$310K	Buy	+20,000	New	+$333K	0.04%	169

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Chilton Capital Management's NVO Position: Q2 2026 in Review

Chilton Capital Management increased its Novo Nordisk (NVO) stake by 1.6% in Q2 2026, buying an estimated $14K and bringing the position to 20,947 shares worth $1M. The position accounts for 0.03% of the portfolio, ranked #130.

Chilton Capital Management first reported a position in NVO in Q2 2013 and has held it in 53 quarters since. The position peaked at $3.16M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

Chilton Capital Management held 20,947 shares of Novo Nordisk worth $1M as of Q2 2026.
Chilton Capital Management bought 326 Novo Nordisk shares in Q2 2026, an estimated $14K.
Novo Nordisk made up 0.03% of Chilton Capital Management's portfolio in Q2 2026, its #130 holding.
Chilton Capital Management first reported a position in Novo Nordisk in Q2 2013 and has held it in 53 quarters since.
Chilton Capital Management's Novo Nordisk position peaked at $3.16M in Q2 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Chilton Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.